-
1.发明申请公开(公告)号：US20180319892A1
公开(公告)日：2018-11-08
申请号：US16024376
申请日：2018-06-29
Applicant: Bristol-Myers Squibb Company
Inventor： David FELTQUATE , Allen C. CHEN
IPC: C07K16/32 , A61K39/395 , A61K31/282
CPC classification number: C07K16/32 , A61K31/282 , A61K31/337 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/55 , C07K16/22 , C07K16/2818 , C07K16/3023 , C07K2317/21 , C07K2317/24 , C07K2317/76 , A61K2300/00
Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
-
2.发明申请公开(公告)号：US20210324106A1
公开(公告)日：2021-10-21
申请号：US17248367
申请日：2021-01-21
Applicant: Bristol-Myers Squibb Company
Inventor： David FELTQUATE , Allen C. CHEN
IPC: C07K16/32 , A61K39/395 , A61K45/06 , C07K16/22 , C07K16/28 , C07K16/30 , A61K31/337 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K33/243 , A61K31/282
Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
-
3.发明公开公开(公告)号：US20230279096A1
公开(公告)日：2023-09-07
申请号：US18090570
申请日：2022-12-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael CARLETON , David FELTQUATE , Olivier DE HENAU , Timothy Patrick REILLY , Tian CHEN , Ye FENG , Shu-Pang Ben HUANG , Ming ZHOU , Ramachandran SURESH
CPC classification number: C07K16/244 , A61P35/04 , A61P35/00 , A61K39/3955 , C07K16/2818 , G01N33/6869 , A61K2039/507
Abstract: Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.
-
4.发明申请公开(公告)号：US20210054063A1
公开(公告)日：2021-02-25
申请号：US16768838
申请日：2019-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael CARLETON , David FELTQUATE , Olivier DE HENAU , Timothy Patrick REILLY , Tian CHEN , Ye FENG , Shu-Pang Ben HUANG , Ming ZHOU , Ramachandran SURESH
Abstract: Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.
-
Patent Agency Ranking
5.发明申请公开(公告)号：US20250011466A1
公开(公告)日：2025-01-09
申请号：US18778430
申请日：2024-07-19
Applicant: Bristol-Myers Squibb Company
Inventor： David FELTQUATE , Allen C. CHEN
IPC: C07K16/32 , A61K31/282 , A61K31/337 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K33/243 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/22 , C07K16/28 , C07K16/30
Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
-
6.发明申请公开(公告)号：US20190263923A1
公开(公告)日：2019-08-29
申请号：US16404593
申请日：2019-05-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , Paul GAGNIER , David FELTQUATE
IPC: C07K16/28 , A61K31/404 , A61K31/506 , A61K45/06 , A61K39/395 , A61K31/44
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
-
7.发明申请公开(公告)号：US20220389110A1
公开(公告)日：2022-12-08
申请号：US17662034
申请日：2022-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , Paul GAGNIER , David FELTQUATE
IPC: C07K16/28 , A61K39/395 , A61K31/404 , A61K45/06 , A61K31/506 , A61K31/44
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
-
8.发明申请公开(公告)号：US20170158776A1
公开(公告)日：2017-06-08
申请号：US15311409
申请日：2015-05-15
Applicant: Bristol-Myers Squibb Company
Inventor： David FELTQUATE , Allen C. CHEN
IPC: C07K16/32 , A61K45/06 , C07K16/22 , A61K31/517 , A61K33/24 , A61K31/519 , A61K31/337 , A61K31/282 , A61K39/395 , A61K31/7068
CPC classification number: C07K16/32 , A61K31/282 , A61K31/337 , A61K31/517 , A61K31/519 , A61K31/555 , A61K31/7068 , A61K33/24 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/55 , C07K16/22 , C07K16/2818 , C07K16/3023 , C07K2317/21 , C07K2317/24 , C07K2317/76 , A61K2300/00
Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, bevacizumab, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
-
9.发明申请公开(公告)号：US20170088626A1
公开(公告)日：2017-03-30
申请号：US15122827
申请日：2015-03-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , Paul GAGNIER , David FELTQUATE
IPC: C07K16/28 , A61K31/404 , A61K31/506 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2896 , A61K31/404 , A61K31/44 , A61K31/506 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2818 , A61K2300/00
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.035 seconds)
